Haplogen and Cyclenium Pharma announce research and development collaboration
Posted: 12 May 2015 | Victoria White
Cyclenium Pharma and Haplogen have signed a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas…
Cyclenium Pharma, an emerging pharmaceutical company specializing in the research and development of novel drug candidates based on its proprietary macrocyclic chemistry technology, and Haplogen, a biotechnology company developing anti-infective drugs, have signed a research agreement aimed at the discovery of novel pharmaceutical candidates in multiple disease areas.
The collaboration brings together two next generation drug discovery platforms: Cyclenium’s CMRT™ Technology-derived QUEST Library™ and associated hit-to-lead optimisation expertise with Haplogen’s unique haploid genetics technology and expertise in host target identification, validation and screening.
Companies will initially focus on anti-viral Haplogen targets
The companies will initially focus on certain anti-viral Haplogen targets, with targets in other therapeutic indications being phased-in as the research progresses.
Biomarkers aren’t just supporting drug discovery – they’re driving it
FREE market report
From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
What you’ll unlock:
- How biomarkers are guiding dose selection and early efficacy decisions in complex trials
- Why multi-omics, liquid biopsy and digital tools are redefining the discovery process
- What makes lab data regulatory-ready and why alignment matters from day one
Explore how biomarkers are shaping early drug development
Access the full report – it’s free!
For Cyclenium, this is the fifth discovery collaboration established over the past year.
“We are extremely excited about the potential of this research collaboration with Haplogen, the leader in applying cutting-edge haploid genetics technology for drug discovery,” stated Helmut Thomas, Ph.D., President & CEO of Cyclenium Pharma. “It was immediately apparent to us that Haplogen’s proven expertise and success in identifying and characterizing novel host factors together with our proprietary CMRT™ macrocyclic chemistry technology would be a powerful combination for the discovery and development of new therapeutic agents.”
“Cyclenium’s proprietary macrocyclic library appears ideal for use against the challenging anti-viral and other targets identified using our haploid genetics platform,” stated Georg Casari, Ph.D., CEO of Haplogen. “We look forward to working with their experienced and successful research team in progressing our drug discovery programs.”
Related topics
Drug Discovery, Hit-to-Lead
Related organisations
Cyclenium Pharma, Haplogen GmbH
